Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Calculators
Our Services
My Account
Do not call
En
Learn about Symbiotec Pharmalab Limited’s Draft Red Herring Prospectus filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.
Symbiotec Pharmalab Limited, an important player in the specialty pharmaceuticals and active pharmaceutical ingredients (API) sector, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for its planned Initial Public Offering (IPO). This filing is an important step in the company's journey towards raising capital from the public markets. The company operates in the manufacturing of APIs, pharmaceutical intermediates, and specialty chemicals for both domestic and international markets.
The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.
Symbiotec Pharmalab Limited has formally filed its Draft Red Herring Prospectus (DRHP) in December 2025, marking the beginning of the IPO process. The filing is currently under regulatory review by SEBI, which will provide feedback and observations. Following this, the company will address the feedback and proceed with the next steps, which include the publication of the Red Herring Prospectus (RHP) and the announcement of the issue dates. Symbiotec Pharmalab plans to list its equity shares on both the NSE and BSE, subject to the receipt of regulatory clearances.
According to the DRHP, the IPO will consist of both a fresh issue of equity shares and an offer for sale (OFS) by existing shareholders. The fresh issue component will raise capital directly for the company, while the OFS component will allow existing shareholders to partially liquidate their holdings. Below are the preliminary details about the issue structure:
| Particulars | Details |
|---|---|
Issue Type |
Fresh Issue of Equity Shares (along with Offer for Sale) |
Face Value |
₹10 per equity share |
Issue Size |
To be determined upon price band finalisation |
Price Band |
To be announced in RHP |
Book Running Lead Manager |
To be disclosed in the RHP |
Registrar to the Issue |
To be disclosed in the RHP |
Proposed Listing |
NSE and BSE |
These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.
Symbiotec Pharmalab Limited operates in the pharmaceutical manufacturing sector, specialising in the production of APIs, pharmaceutical intermediates, and specialty chemicals. It caters to both domestic pharmaceutical manufacturers and international clients. The company's product portfolio includes a wide range of pharmaceutical ingredients, all of which are developed to meet rigorous quality and regulatory standards.
With its extensive manufacturing infrastructure and regulatory certifications, Symbiotec Pharmalab is positioned to serve growing demands in the global pharmaceutical market. The company’s manufacturing processes comply with high-quality standards, ensuring the production of safe and effective products for the pharmaceutical and chemical industries.
Symbiotec Pharmalab Limited intends to use the proceeds from the fresh issue for several key purposes, aimed at enhancing its operational capabilities and supporting long-term business growth:
| Fund Allocation | Purpose |
|---|---|
Capital Expenditure |
Expansion of manufacturing facilities and equipment acquisition |
Research and Development |
Development of new APIs and pharmaceutical intermediates |
Working Capital Requirements |
Increased raw material procurement and operational costs |
Debt Repayment |
To improve financial leverage and reduce borrowing costs |
General Corporate Purposes |
Administrative expenses and operational flexibility |
Symbiotec Pharmalab has shown solid growth in its operations, with key financial performance metrics available in the DRHP. The company’s financial results provide an insight into its growing revenue base and strong profitability across various segments of its business.
| Fiscal Year / Period | Revenue (₹ Cr) | EBITDA (₹ Cr) | PAT (₹ Cr) | Key Highlights |
|---|---|---|---|---|
FY24 (Year ended Mar 31, 2024) |
As per DRHP |
As per DRHP |
As per DRHP |
Detailed audited financials available in DRHP |
FY25 (Year ended Mar 31, 2025) |
As per DRHP |
As per DRHP |
As per DRHP |
Full audited financials in RHP filing |
H1 FY26 (Apr–Jul 31, 2025) |
As per DRHP |
As per DRHP |
As per DRHP |
Interim period performance available in DRHP |
*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.
The timeline of the IPO process includes several milestones as detailed below:
| Milestone / Stage | Date (or Status) | Details |
|---|---|---|
DRHP filed with SEBI |
December 2025 |
Draft Red Herring Prospectus filed for regulatory review |
SEBI observations |
Awaited |
Feedback and approval expected post-DRHP review |
Red Herring Prospectus (RHP) |
Awaited |
To be filed post-SEBI approval |
IPO Opening Date |
To be announced |
Final dates will be notified once SEBI approval is received |
IPO Closing Date |
To be announced |
Dependent on official notification |
Allotment of Shares |
To be announced |
Allotment post-closing and basis of allotment |
Listing on NSE/BSE |
To be announced |
Listing upon completion of allotment and regulatory formalities |
Note: Investors should refer to official filings for final IPO dates to learn more about Symbiotec Pharmalab Limited IPO listing details and price, and listing timelines.
This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner
Symbiotec Pharmalab Limited filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) in December 2025, officially initiating the process for launching its initial public offering (IPO) in India.
The proposed issue size for Symbiotec Pharmalab Limited’s IPO has not yet been finalised. The company will disclose the total issue amount in the Red Herring Prospectus (RHP) after determining the final price band for the offering.
Symbiotec Pharmalab Limited intends to utilise the IPO proceeds to expand its manufacturing facilities, strengthen research and development initiatives, enhance working capital, repay existing borrowings, and support other general corporate growth objectives aimed at long-term business expansion.
As of now, SEBI’s approval for Symbiotec Pharmalab Limited’s IPO is pending. The company will move forward with the next phase of the IPO process after obtaining SEBI’s clearance and completing statutory compliance requirements.
The Symbiotec Pharmalab Limited IPO holds significance as it allows investors to participate in the company’s planned public offering. The raised funds will enhance production capacity, strengthen R&D, and boost competitiveness in domestic and global pharmaceutical markets.
.jpeg)
250 Views
| 1min read
Posted on 19 Dec
Academy 
.jpeg "image not found"){kind=small}
